Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice
NCT02322008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1035
Last updated 2014-12-23
Summary
Can genetic markers be used to predict anti-TNF response? A cohort was established to identify SNPs associated with anti-TNF therapy in patients with inflammatory bowel disease.
Conditions
Interventions
- BIOLOGICAL
-
infliximab and adalimumab
In this retrospective, observational study, no interventions were undertaken by the researchers.
Sponsors & Collaborators
-
Regionshospitalet Viborg, Skive
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-09-30
- Primary Completion
- 2011-03-31
- Completion
- 2011-03-31
More Related Trials
-
Genetic Studies of Inflammatory Bowel Disease
NCT00340444 ·Status: COMPLETED
-
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
NCT02508012 ·Status: COMPLETED ·Phase: NA
-
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
NCT00851565 ·Status: UNKNOWN ·Phase: PHASE4
-
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)
NCT03088449 ·Status: UNKNOWN
-
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
NCT02316678 ·Status: COMPLETED
-
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
NCT04852666 ·Status: COMPLETED
-
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
NCT02054533 ·Status: COMPLETED
-
Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients
NCT01291810 ·Status: COMPLETED ·Phase: PHASE2
-
Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease
NCT04109300 ·Status: UNKNOWN ·Phase: NA
-
Genome Analysis Across Populations in Inflammatory Bowel Disease
NCT06042387 ·Status: RECRUITING
-
Regulatory T-cells and Crohn's Disease
NCT02060318 ·Status: COMPLETED
-
Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases
NCT02878395 ·Status: UNKNOWN
-
Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients
NCT05040854 ·Status: UNKNOWN
-
Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease
NCT00808262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
NCT01971970 ·Status: COMPLETED
-
Chronic Inflammatory Disease, Lifestyle and Treatment Response
NCT03173144 ·Status: COMPLETED
-
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
NCT00269841 ·Status: COMPLETED ·Phase: PHASE3
-
Cytokines and Genes in Therapeutic Response in Crohn's Disease
NCT03266471 ·Status: COMPLETED
-
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT01988961 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effectiveness of Kits Promonitor-IFX/ADL and Promonitor-Anti-IFX/ADL in Patients With IBD
NCT06666569 ·Status: COMPLETED
-
Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease
NCT03698500 ·Status: UNKNOWN ·Phase: NA
-
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03885713 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Prognosis in IBD Patients
NCT05653011 ·Status: RECRUITING
-
Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess
NCT02856763 ·Status: COMPLETED
-
A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab
NCT07263477 ·Status: COMPLETED